azaguanine and Sjogren-s-Syndrome

Sjögren's syndrome (SjS) is an autoimmune disease with a strong genetic association. To date, no vaccine or therapeutic agent exists to cure SjS, and patients must rely on lifelong therapies to treat symptoms. Human leukocyte antigens (HLA) are primary susceptibility loci that form the genetic basis for many autoimmune diseases, including SjS. In this study, we sought to determine whether blocking MHC class II IAg. Specific peptides of Ro60 autoantigen were identified to bind to IAg. This study presents a novel therapeutic approach for SjS by identifying small molecules capable of inhibiting T cell response via antigen-specific presentation.. CQN is supported financially in part by PHS grants AI130561, DE026450, and DE028544 from the National Institutes of Health.

Topics: Alkanes; Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Azaguanine; Female; Histocompatibility Antigens Class II; Mice; Mice, Inbred NOD; Polycyclic Compounds; Sjogren's Syndrome